Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Provenge Coverage With Data Collection Suggested By MEDCAC Members

Executive Summary

The Centers for Medicare and Medicaid Services got a number of suggestions about linking Medicare coverage with data collection for Dendreon’s therapeutic prostate cancer vaccine Provenge at the Medicare Evidence Development and Coverage Advisory Committee’s Nov. 17 meeting.
Advertisement

Related Content

Medicare Will Cover Provenge Labeled Uses, CMS Proposes; Off-Label Is Up To Contractors
A Closer Look: Decision For No Medicare NCD On ESAs In Renal Disease Would Be The Exception
A Closer Look: Decision For No Medicare NCD On ESAs In Renal Disease Would Be The Exception
FDA/CMS Parallel Review: Firms Lack Incentive To Participate, Lawyers Say
FDA/CMS Parallel Review: Firms Lack Incentive To Participate, Lawyers Say
Prostate Cancer Market Snapshot: More Than Provenge
Prostate Cancer Market Snapshot: More Than Provenge
Provenge Data Not Supportive Of Off-Label Uses, MEDCAC Finds
Provenge Outcomes Data "Moderately" Strong For Labeled Use; Off-Label Insufficient, AHRQ Tech Assessment Says
Funding, Authority Questions Hinder Coverage With Evidence Development

Topics

Advertisement
UsernamePublicRestriction

Register

PS052860

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel